FREDERICK, Md., Feb. 14 /PRNewswire-FirstCall/ -- BioElectronics Corporation announced today that it has filed a Form SB-2 Registration Statement with the Securities and Exchange Commission in connection with the sale of shares of common stock by the Company in a direct offering and by selling shareholders.
BioElectronics Corporation is the maker of ActiPatch(TM), the drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers continuous pulsed therapy. The ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics Corporation
CONTACT: Andrew J. Whelan, President & CEO, or Thomas O’Connor, EVPOperations & COO, both of BioElectronics Corporation, +1-301-644-3906, orFax, +1-301-644-3939, or info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com//
